Abbott Reports Second-Quarter 2025 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Abbott Labs (ABT) PT Lowered to $155 at Citi
July 18, 2025 10:03 AM EDTCiti analyst Joanna Wuensch lowered the price target on Abbott Labs (NYSE: ABT) to $155.00 (from $157.00) while maintaining a Buy rating.
The analyst comments "This was a somewhat precarious setup for ABT heading into the quarter, priced for a beat-and-raise, which did not... More
Goldman Sachs Reiterates Buy Rating on Abbott Labs (ABT)
July 17, 2025 9:45 AM EDTGoldman Sachs analyst David Roman reiterated a Buy rating and $153.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "This morning, Abbott reported 2Q25 results and updated 2025 guidance. The headline that we expect to gain most attention is the reduction to the... More
Abbott (ABT) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY25 EPS Guidance
July 17, 2025 7:31 AM EDTAbbott (NYSE: ABT) reported Q2 EPS of $1.26, $0.01 better than the analyst estimate of $1.25. Revenue for the quarter came in at $11.42 billion versus the consensus estimate of $11.07 billion.
GUIDANCE:
Abbott sees FY2025 EPS of $5.10-$5.20, versus the consensus of $5.16.
For earnings history and earnings-related data on Abbott (ABT) click here.
... More